Positive data from STAR study of NanoKnife system in Pancreatic Cancer-AngioDynamics

Results from the Soft Tissue Ablation Registry (STAR), demonstrate that irreversible electroporation (IRE) with the NanoKnife System, from AngioDynamics, in combination with standard chemotherapy, doubled the overall survival rate of locally advanced (Stage III) pancreatic cancer patients to nearly 24 months. All patients in the STAR study underwent induction chemotherapy with 52 percent receiving chemo-radiation, for a median of 7 months (range, 5-13) prior to IRE. IRE was successfully administered to all patients. Nineteen percent sustained complications with a median grade of 2 (range 1-3). Median length of stay was 6 days (range, 4-58) with a median follow-up of 25 months. Six patients (3%) had local recurrence. Median overall survival in both groups was 23.5 months. The data was presented at the American Surgical Association annual meeting.